Clinical Report: Kidney Cancer Conference Highlights from ASCO GU 2025
Overview
The ASCO GU 2025 conference presented significant updates in kidney cancer treatment, particularly regarding the efficacy of triplet therapy and novel biomarkers. Notably, COSMIC-313 showed improved progression-free survival (PFS) but no overall survival (OS) benefit for cabozantinib combined with nivolumab and ipilimumab in intermediate/poor-risk clear cell renal cell carcinoma (ccRCC).
Background
Kidney cancer remains a critical area of research due to its rising incidence and the complexity of treatment options. Recent advancements in immunotherapy and targeted therapies have transformed the management of advanced clear cell renal cell carcinoma (ccRCC). Understanding the latest clinical trial outcomes is essential for optimizing patient care and treatment strategies.
Data Highlights
No numerical data available in the provided source material.
Key Findings
- COSMIC-313 demonstrated improved PFS for cabozantinib plus nivolumab and ipilimumab in intermediate/poor-risk ccRCC, but no OS benefit was observed.
- CheckMate 9ER confirmed that nivolumab and cabozantinib significantly improved OS compared to sunitinib in first-line treatment.
- KIM1 was identified as a promising biomarker for predicting immunotherapy benefits in ccRCC.
- Patients with favorable risk showed tumor response improvements but lacked OS benefits with cabozantinib and nivolumab.
- Triplet therapy may affect dose intensity, as evidenced by lower median doses of cabozantinib in COSMIC-313.
Clinical Implications
Clinicians should consider the risk stratification of patients when selecting treatment regimens, as those with intermediate or poor-risk disease may benefit more from aggressive therapy. The identification of KIM1 as a biomarker could enhance patient selection for immunotherapy, potentially improving outcomes.
Conclusion
The findings from ASCO GU 2025 underscore the evolving landscape of kidney cancer treatment, highlighting the need for ongoing research to optimize therapeutic strategies and improve patient outcomes.
References
- Dana-Farber, Kidney Cancer Highlights from ASCO 2025
- Dana-Farber, Kidney Cancer Highlights presented by Michael Serzan, MD
- ASCO GU 2025: Cabozantinib in Combination with Nivolumab and Ipilimumab
- Circulating kidney injury molecule-1 (KIM-1) and association with outcome to adjuvant immunotherapy in renal cell carcinoma
- dana-farber — Bladder Cancer Conference Highlights from ASCO GU 2025
- the asco post — Genitourinary Oncology Highlights: Treatment Advances in Renal Cell, Bladder, Urothelial, and Prostate Cancers
- Renal cell carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up - ScienceDirect
- ASCO GU 2025: Cabozantinib in Combination with Nivolumab and Ipilimumab in Previously Untreated Advanced Renal Cell Carcinoma (aRCC): Final Results of COSMIC-313
- Circulating kidney injury molecule-1 (KIM-1) and association with outcome to adjuvant immunotherapy in renal cell carcinoma - PubMed
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
